CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $7.8B, above the global median of $1.18B
- PositionOperating margin is 45.7%, higher than 95% of its Biotechnology peers (median -24.1%)
- Interpretations16 currently firing — 16
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.03%
Annual Rate
CNY 1.20Paid semi-annual
Last Ex-Dividend
Jun 1, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
52.42BCNY7.80B · vs all stocks (USD)
Trailing P/E
22.45xvs Biotechnology peers
Revenue (TTM)
5.67BCNY843.59M · vs all stocks (USD)
Profit Margin
42.57%vs Biotechnology peers
Beta
0.0180xvs all stocks
52-Week Change
28.37%vs all stocks
Forward Annual Dividend Yield
1.03%vs all stocks
Market Capitalization
52.42BCNY7.80B · vs all stocks (USD)
Enterprise Value
49.26BCNY7.33B · vs all stocks (USD)
Trailing P/E
22.45xvs Biotechnology peers
Forward P/E
16.55xvs Biotechnology peers
Price to Sales (TTM)
9.54xvs Biotechnology peers
Price to Book (MRQ)
6.99xvs Biotechnology peers
Enterprise to Revenue
8.68xvs Biotechnology peers
Enterprise to EBITDA
18.87xvs Biotechnology peers
Gross Margin
94.91%vs Biotechnology peers
Profit Margin
42.57%vs Biotechnology peers
Operating Margin
45.71%vs Biotechnology peers
Return on Assets (TTM)
21.68%vs Biotechnology peers
Return on Equity (TTM)
36.09%vs Biotechnology peers
Revenue (TTM)
5.67BCNY843.59M · vs all stocks (USD)
Revenue per Share (TTM)
12.59CNYUpdated Aug 21, 2026Quarterly Revenue Growth
44.20%vs Biotechnology peers
Gross Profit (TTM)
5.46BCNY812.46M · vs all stocks (USD)
EBITDA (TTM)
2.60BCNY385.95M · vs all stocks (USD)
Net Income (TTM)
2.41BCNY359.08M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
54.90%vs Biotechnology peers
Operating Cash Flow (TTM)
2.48BCNY369.37M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.45BCNY214.90M · vs all stocks (USD)
Forward Annual Dividend Rate
1.20CNYUpdated Aug 21, 2026Forward Annual Dividend Yield
1.03%vs all stocks
Trailing Annual Dividend Rate
1.00CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.86%vs all stocks
Revenue
5.19BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
164.58MCNYFY2025 · Dec 31, 2025Gross Profit
5.02BCNYFY2025 · Dec 31, 2025Operating Income
2.48BCNY369.00M · vs all stocks (USD)
Pre-tax Income
2.54BCNYFY2025 · Dec 31, 2025Income Tax Expense
355.83MCNYFY2025 · Dec 31, 2025Net Income
2.19BCNYFY2025 · Dec 31, 2025EBIT
2.55BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
2.55BCNYFY2025 · Dec 31, 2025Research & Development
413.37MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.40BCNYFY2025 · Dec 31, 2025Other Operating Expenses
70.99MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
54.49MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
130.20KCNYFY2025 · Dec 31, 2025EPS (Basic)
4.86CNYFY2025 · Dec 31, 2025EPS (Diluted)
4.86CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
450.43MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
450.43MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
2.19BCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
2.11BCNYFY2025 · Dec 31, 2025Free Cash Flow
1.93BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
445.72MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
2.19BCNYFY2025 · Dec 31, 2025Stock-based Compensation
25.43MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-42.16MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-13.63MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-46.89MCNYFY2025 · Dec 31, 2025Capital Expenditures
-186.00MCNYFY2025 · Dec 31, 2025Sale of Investments
92.90MCNYFY2025 · Dec 31, 2025Other Investing Activity
-1.94BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-2.04BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-360.00MCNYFY2025 · Dec 31, 2025Other Financing Charges
-3.02MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-363.02MCNYFY2025 · Dec 31, 2025Shares Outstanding
450.00MSharesUpdated Aug 21, 2026Float Shares
224.78MSharesUpdated Aug 21, 2026% Held by Insiders
54.02%vs all stocks
% Held by Institutions
13.99%vs all stocks
Total Cash (MRQ)
3.16BCNY469.75M · vs all stocks (USD)
Total Cash per Share (MRQ)
7.02CNYUpdated Aug 21, 2026Total Debt (MRQ)
4.41MCNY655.67K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0006xvs Biotechnology peers
Current Ratio (MRQ)
5.25xvs Biotechnology peers
Book Value per Share (MRQ)
17.21CNYUpdated Aug 21, 2026Total Assets
7.90BCNY1.18B · vs all stocks (USD)
Total Current Assets
4.17BCNYFY2025 · Dec 31, 2025Total Liabilities
821.48MCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.73BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
15.86MCNYFY2025 · Dec 31, 2025Total Current Liabilities
805.62MCNYFY2025 · Dec 31, 2025Cash
671.22MCNYFY2025 · Dec 31, 2025Cash Equivalents
3.32MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
674.54MCNYFY2025 · Dec 31, 2025Other Short-term Investments
2.51BCNYFY2025 · Dec 31, 2025Accounts Receivable
375.60MCNYFY2025 · Dec 31, 2025Inventory
71.66MCNYFY2025 · Dec 31, 2025Accounts Payable
102.72MCNYFY2025 · Dec 31, 2025Short-term Debt
1.87MCNYFY2025 · Dec 31, 2025Long-term Debt
2.01MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
3.27MCNYFY2025 · Dec 31, 2025Common Stock (Book)
450.00MCNYFY2025 · Dec 31, 2025Retained Earnings
3.01BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
7.08BCNY1.05B · vs all stocks (USD)
52-Week Low
78.82CNYUpdated Aug 21, 202652-Week High
138.30CNYUpdated Aug 21, 202652-Week Change
28.37%vs all stocks
Beta
0.0180xvs all stocks
50-Day MA
111.48CNYUpdated Aug 21, 2026200-Day MA
100.39CNYUpdated Aug 21, 2026Avg 10-Day Volume
10.20MSharesUpdated Aug 21, 2026Avg 30-Day Volume
11.24MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
5.36CNYUpdated Aug 21, 202616 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
How is this stock valued?
Down-Close Streak With Profitability
A run of down weeks on a company profitable three years running and funded by equity.
Reads
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 45.7%, higher than 95% of its Biotechnology peers (median -24.1%)Significant
Operating margin: 0.46Industry median: -0.24Industry P95: 0.38Peers compared: 194
Profit margin is 42.6%, higher than 95% of its Biotechnology peers (median -32.5%)Significant
Profit margin: 0.43Industry median: -0.32Industry P95: 0.39Peers compared: 194
Return on equity is 36.1%, higher than 95% of its Biotechnology peers (median -23.6%)Significant
Return on equity: 0.36Industry median: -0.24Industry P95: 0.23Peers compared: 194
Return on assets is 21.7%, higher than 95% of its Biotechnology peers (median -21.3%)Significant
Return on assets: 0.22Industry median: -0.21Industry P95: 0.19Peers compared: 194
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.12×)Notable
Debt-to-equity: 0.00Industry median: 0.12Industry P5: 0.00Peers compared: 194
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.83
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $7.8B, above the global median of $1.18BNotable
Market cap (USD): 7,796,121,750Global Median: 1,179,398,897.704
Revenue is $843.59M, above the global median of $534.05MNotable
Revenue (USD): 843,592,989.327Global Median: 534,052,387.958
Levered free cash flow is $214.9M, above the global median of $19.19MNotable
Levered free cash flow (USD): 214,904,727.909Global Median: 19,189,974.917
Companies that share the same coordination system — how they create, deliver, or capture value.
InnoCare Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Rhythm Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
ALK-Abello A/S
Tier 1ProductionApproval-Gated PipelineRule
Huadong Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Spyre Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Glenmark Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alkermes plc
Tier 1ProductionApproval-Gated PipelineRule
Demant A/S
Tier 1ProductionApproval-Gated PipelineFlowRule
Grifols, S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Scholar Rock Holding Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
NVIDIA Corporation
15 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin
Games Workshop Group PLC
14 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin
Catalyst Pharmaceuticals Inc.
14 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin